UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
04
October 2024 - “Holding(s) in
Company”
|
99.1
4 October 2024
HALEON PLC
("Haleon" or "the Company")
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
|
GB00BMX86B70
|
Issuer Name
|
HALEON PLC
|
UK or Non-UK Issuer
|
UK
|
2. Reason for Notification
|
An acquisition or disposal of voting rights
|
3. Details of person subject to the notification
obligation
Name
|
Pfizer Inc.
|
City of registered office (if applicable)
|
New York
|
Country of registered office (if applicable)
|
United States of America
|
4. Details of the shareholder
|
Name
|
City
of registered office
|
Country
of registered office
|
|
State
Street Nominees Limited
|
London
|
United
Kingdom
|
|
Guaranty Nominees
Limited
|
London
|
United
Kingdom
|
5. Date on which the threshold was crossed or reached
|
03-Oct-2024
|
6. Date on which Issuer notified
|
03-Oct-2024
|
7. Total positions of person(s) subject to the notification
obligation
|
|
%
of voting rights attached to shares (total of 8.A)
|
%
of voting rights through financial instruments (total of 8.B 1 +
8.B 2)
|
Total
of both in % (8.A + 8.B)
|
Total
number of voting rights held in issuer
|
|
Resulting situation
on the date on which threshold was crossed or reached
|
15.040000
|
0.000000
|
15.040000
|
1361709764
|
|
Position of
previous notification (if applicable)
|
22.580000
|
0.000000
|
22.580000
|
|
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached
8A. Voting rights attached to shares
|
Class/Type of shares ISIN code(if possible)
|
Number of direct voting rights (DTR5.1)
|
Number of indirect voting rights (DTR5.2.1)
|
% of direct voting rights (DTR5.1)
|
% of indirect voting rights (DTR5.2.1)
|
|
Ordinary Shares
GB00BMX86B70
|
|
967251860
|
|
10.680000
|
|
Restricted
ADSs
|
|
394457904
|
|
4.360000
|
|
Sub
Total 8.A
|
1361709764
|
15.040000%
|
||
8B1. Financial Instruments according to (DTR5.3.1R.(1)
(a))
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Number of voting rights that may be acquired if the instrument is
exercised/converted
|
% of voting rights
|
|
|
|
|
|
|
|
Sub
Total 8.B1
|
|
|
|
|
8B2. Financial Instruments with similar economic effect according
to (DTR5.3.1R.(1) (b))
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Physical or cash settlement
|
Number of voting rights
|
% of voting rights
|
|
|
|
|
|
|
|
|
Sub
Total 8.B2
|
|
|
|
||
9. Information in relation to the person subject to the
notification obligation
|
1. Person subject to the notification obligation is not controlled
by any natural person or legal entity and does not control any
other undertaking(s) holding directly or indirectly an interest in
the (underlying) issuer.
|
|
Ultimate controlling person
|
Name of controlled undertaking
|
% of voting rights if it equals or is higher than the notifiable
threshold
|
% of voting rights through financial instruments if it equals or is
higher than the notifiable threshold
|
Total of both if it equals or is higher than the notifiable
threshold
|
|
|
|
|
|
|
10. In case of proxy voting
Name of the proxy holder
|
|
The number and % of voting rights held
|
|
The date until which the voting rights will be held
|
|
11. Additional Information
|
This notification relates to the sale by Pfizer Inc. ("Pfizer") of
a portion of its interest in Haleon plc ("Haleon").Pfizer sold
640,000,000 Haleon ordinary shares ("Ordinary Shares") pursuant to
a secondary offering announced on 30 September 2024. In connection
with the offering, and in addition to the 640,000,000 Ordinary
Shares in the offering, Pfizer sold 60,526,315 Ordinary Shares to
Haleon in an off-market sale in accordance with the terms of a
share purchase deed between Haleon and Pfizer that was previously
approved by Haleon's shareholders.These calculations are based on
Haleon's issued voting share capital of 9,053,360,882 ordinary
shares with voting rights, as communicated by Haleon in their
announcement on total voting rights and capital dated 3 October
2024.Pfizer holds its ordinary shares in Haleon through (i) State
Street Nominees Limited, and (ii) Guaranty Nominees Limited (in
respect of its American depositary shares representing Ordinary
Shares), which hold the legal title to those shares on Pfizer's
behalf.
|
12. Date of Completion
|
03-Oct-2024
|
13. Place Of Completion
|
New York
|
Amanda Mellor, Company Secretary
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date: October 04, 2024
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|